Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Decreased by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D reduced its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 25.9% during the second quarter, Holdings Channel.com reports. The firm owned 25,145 shares of the specialty pharmaceutical company’s stock after selling 8,776 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Jazz Pharmaceuticals were worth $2,684,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Allspring Global Investments Holdings LLC raised its stake in shares of Jazz Pharmaceuticals by 0.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock valued at $1,937,000 after purchasing an additional 99 shares in the last quarter. ProShare Advisors LLC raised its position in Jazz Pharmaceuticals by 1.4% in the first quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock worth $896,000 after acquiring an additional 105 shares in the last quarter. Ontario Teachers Pension Plan Board raised its position in Jazz Pharmaceuticals by 0.4% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock worth $3,659,000 after acquiring an additional 108 shares in the last quarter. Pinnacle Associates Ltd. raised its position in Jazz Pharmaceuticals by 1.1% in the first quarter. Pinnacle Associates Ltd. now owns 10,371 shares of the specialty pharmaceutical company’s stock worth $1,249,000 after acquiring an additional 110 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.8 %

Shares of NASDAQ JAZZ opened at $109.57 on Thursday. The stock has a market cap of $6.91 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 1.31 and a beta of 0.57. The business has a 50 day simple moving average of $110.58 and a 200 day simple moving average of $111.14. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $137.38. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating the consensus estimate of $3.80 by $0.87. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. On average, research analysts predict that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on JAZZ. Wells Fargo & Company dropped their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Morgan Stanley cut their price objective on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. Piper Sandler cut their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. Robert W. Baird cut their price objective on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. Finally, Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $173.07.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.